{"id":"bucy","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Graft-versus-host disease (GVHD)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Busulfan is an alkylating agent that causes DNA cross-linking and cell death, while cyclophosphamide is a nitrogen mustard alkylating agent that also damages DNA. Together, they provide myeloablative conditioning to eliminate malignant cells and suppress the patient's immune system to allow engraftment of donor stem cells in transplant recipients.","oneSentence":"BuCy is a chemotherapy conditioning regimen combining busulfan and cyclophosphamide used to prepare patients for hematopoietic stem cell transplantation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:55:08.042Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Conditioning regimen for hematopoietic stem cell transplantation in hematologic malignancies"},{"name":"Preparation for allogeneic or autologous bone marrow transplantation"}]},"trialDetails":[{"nctId":"NCT07183878","phase":"NA","title":"Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-08-20","conditions":"Acute Myeloid Leukemia, High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":138},{"nctId":"NCT07108530","phase":"PHASE2","title":"Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multicenter Study","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-06","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT05470777","phase":"PHASE2","title":"CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2020-01-19","conditions":"B-cell Acute Lymphoblastic Leukemia","enrollment":37},{"nctId":"NCT06673459","phase":"PHASE3","title":"BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-12-01","conditions":"T-Cell Lymphocytic Leukemia, ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION, Total Body Irradiation","enrollment":430},{"nctId":"NCT05907486","phase":"PHASE3","title":"The Use of N-acetylcysteine for Thrombotic Events After Allogenic Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-08-01","conditions":"Thrombotic Disorder","enrollment":260},{"nctId":"NCT05823714","phase":"PHASE2","title":"Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-01-20","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":70},{"nctId":"NCT05809167","phase":"PHASE2","title":"Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-01-20","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia","enrollment":55},{"nctId":"NCT05453552","phase":"PHASE2, PHASE3","title":"G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2022-07-01","conditions":"Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning","enrollment":242},{"nctId":"NCT05739630","phase":"PHASE2, PHASE3","title":"M-PTCy vs BuCy in Haploidentical HSCT for Acute Leukemia","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-01-01","conditions":"Acute Leukemia","enrollment":60},{"nctId":"NCT05559450","phase":"PHASE2","title":"Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALL","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-02-01","conditions":"B-cell Acute Lymphoblastic Leukemia","enrollment":80},{"nctId":"NCT05449899","phase":"PHASE2, PHASE3","title":"G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2022-07","conditions":"Secondary Acute Myeloid Leukemia Evolving From MDS, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning","enrollment":232},{"nctId":"NCT05379569","phase":"PHASE4","title":"Comparative Study of BFC and BuCy Conditioning Regimen for Allo-PBSCT in Acute B-cell ALL","status":"UNKNOWN","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2022-05-15","conditions":"Acute B Lymphoblastic Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation","enrollment":142},{"nctId":"NCT02670252","phase":"PHASE3","title":"BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-01","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Total Body Irradiation","enrollment":550},{"nctId":"NCT02744742","phase":"PHASE2, PHASE3","title":"G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-04-18","conditions":"Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning","enrollment":202},{"nctId":"NCT04713956","phase":"PHASE2, PHASE3","title":"G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2021-01-15","conditions":"Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning","enrollment":242},{"nctId":"NCT02671708","phase":"PHASE2, PHASE3","title":"IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT","status":"COMPLETED","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-01","conditions":"Autologous Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Conditioning","enrollment":153},{"nctId":"NCT03385096","phase":"PHASE2, PHASE3","title":"Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-01-02","conditions":"Autologous Hematopoietic Stem Cell Transplantation, Conditioning, Multiple Myeloma","enrollment":122},{"nctId":"NCT03339700","phase":"PHASE2","title":"Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic Leukemia","status":"UNKNOWN","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2018-09-15","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":15},{"nctId":"NCT02605460","phase":"PHASE2","title":"Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission","status":"UNKNOWN","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2014-02","conditions":"Acute Myeloid Leukemia, Acute Lymphoid Leukemia","enrollment":20},{"nctId":"NCT04123392","phase":"PHASE2, PHASE3","title":"Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2019-10","conditions":"TP53, Myeloid Tumors, Conditioning","enrollment":196},{"nctId":"NCT04098653","phase":"PHASE2, PHASE3","title":"Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2019-09","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Myeloid Tumors","enrollment":196},{"nctId":"NCT03596892","phase":"PHASE2, PHASE3","title":"Decitabine+BUCY vs BUCY Conditioning Regimen for MLL+ Acute Leukemia Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-07","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation, Conditions, Mixed-lineage-leukemia (MLL)-Rearranged Acute Leukemia","enrollment":122},{"nctId":"NCT03229616","phase":"PHASE2, PHASE3","title":"BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2017-07-05","conditions":"Autologous Hematopoietic Stem Cell Transplantation, Diffuse Large B-cell Lymphoma, Conditioning","enrollment":122},{"nctId":"NCT03256071","phase":"PHASE2, PHASE3","title":"Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2017-09","conditions":"Acute Myeloid Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning","enrollment":90},{"nctId":"NCT00248547","phase":"NA","title":"Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2004-05","conditions":"Cancer","enrollment":40},{"nctId":"NCT02328950","phase":"","title":"A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome","status":"UNKNOWN","sponsor":"Fujian Medical University","startDate":"2014-12","conditions":"Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":50},{"nctId":"NCT01766375","phase":"PHASE3","title":"the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2012-08","conditions":"Acute Myeloid Leukemia","enrollment":200},{"nctId":"NCT00774280","phase":"PHASE3","title":"Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen","status":"COMPLETED","sponsor":"Cooperative Study Group A for Hematology","startDate":"2002-05","conditions":"Leukemia, Myelodysplastic Syndrome","enrollment":130}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":746,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BuCy","genericName":"BuCy","companyName":"The First Affiliated Hospital of Soochow University","companyId":"the-first-affiliated-hospital-of-soochow-university","modality":"Biologic","firstApprovalDate":"","aiSummary":"BuCy is a chemotherapy conditioning regimen combining busulfan and cyclophosphamide used to prepare patients for hematopoietic stem cell transplantation. Used for Conditioning regimen for hematopoietic stem cell transplantation in hematologic malignancies, Preparation for allogeneic or autologous bone marrow transplantation.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}